Unlock this StockReport nowClick to Unlock

GlaxoSmithKline Share Price

GSK 1593p 16.6  1.1%
24/06/19 1.50k
StockRank

Momentum
Relative Strength (%)
1m
3m
1yr
Volume Change (%)
10d v 3m
Price vs... (%)
52w High
50d MA
200d MA
vs.
market
vs.
industry
Growth & Value
Margin of Safety (beta)
Screens Passed 2 / 1
Balance Sheet · Income Statement · Cashflow Financial Summary
Year End 31st Dec 2013 2014 2015 2016 2017 2018 TTM 2019E 2020E CAGR / Avg
Revenue £m
Operating Profit £m
Net Profit £m
EPS Reported p
EPS Normalised p
EPS Growth %
PE Ratio x
PEG x
Profitability
Operating Margin %
ROA %
ROCE %
ROE %
Cashflow
Op. Cashflow ps p
Capex ps p
Free Cashflow ps p
Last ex-div: 16th May, paid: 11th Jul more... Dividends
Dividend ps p
Dividend Growth %
Dividend Yield %
Dividend Cover x
Balance Sheet
Cash etc £m
Working Capital £m
Net Fixed Assets £m
Net Debt £m
Book Value £m
Average Shares m
Book Value ps p -9.3%

FINANCIAL BRIEF: For the three months ended 31 March 2019, GlaxoSmithKline plc revenues increased 6% to £7.66B. Net income increased 51% to £830M. Revenues reflect Vaccines segment increase of 23% to £1.52B, Pharmaceuticals segment increase of 4% to £4.16B, Consumer Healthcare segment remaining flat at £1.98B, US segment increase of 17% to £2.96B, Rest of world segment increase of 4% to £2.77B. more »

Health Trend
Bankruptcy Risk
  Earnings Manipulation Risk
Magic Formula Score
B-
B-
Other Ratios
Leverage (ttm) Total -Intang +Pension
Gross Gearing %
Net Gearing %
Cash / Assets %
vs.
market
vs.
industry
Recent History
Latest interim period (ended 31st Mar '19) vs. prior year
Sales Growth %
EPS Growth %
3yr Compound Annual Growth Rate
Sales Growth %
EPS Growth %
DPS Growth %

Broker Forecasts
31st Dec 2019
31st Dec 2020

Price Target: 16.3
(+3.71% above Price)
Net Profit EPS DPS Net Profit EPS DPS
Est. Long Term Growth Rate: +5.0% (£) (p) (p) (£) (p) (p)
Consensus Estimate
1m Change
3m Change
22 brokers Broker Consensus Trend
Broker Recommendations for GlaxoSmithKline
Recommendation:Strong SellSellHoldBuyStrong Buy
No. of Analysts: 0 2 13 4 3

Named Brokers and Analysts
Bank of America Merrill Lynch Graham Parry , Deutsche Bank Richard Parkes , Cowen and Company Stephen Scala , Jefferies Peter Welford , HSBC Stephen McGarry , Credit Suisse - North America Rebekah Harper , Piper Jaffray , Morgan Stanley , Citi Andrew Baum , SVB Leerink John Sullivan , BERNSTEIN , Investec Bank (UK) Plc Andrew Whitney , Goldman Sachs Research Keyur Parekh , UBS Equities Alexandra Hauber , Natixis , Exane BNP Paribas , Societe Generale Justin Smith , JPMorgan James Gordon , Berenberg , DZ Bank Elmar Kraus , ODDO BHF Martial Descoutures , Kepler Cheuvreux David Evans , Wolfe Research Tim Anderson , Barclays Emmanuel Papadakis , Shore Capital Stockbrokers Adam Barker , Bryan Garnier Jean-Jacques Le Fur , MainFirst Bank AG , Morningstar, Inc. Damien Conover , Day by Day Valérie GASTALDY , Landesbank Baden-Wuerttemberg Timo Kuerschner , Liberum Naresh Chouhan , Guggenheim Securities LLC Seamus Fernandez , Alphavalue Kamla Singh , Cantor Fitzgerald Europe Brian White , Beaufort Securities (Historical) ,

Profile Summary

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases. The Company makes a range of prescription medicines, vaccines and consumer healthcare products. The Pharmaceuticals business discovers, develops and commercializes medicines to treat a range of acute and chronic diseases. The Vaccines business provides vaccines for people of all ages from babies and adolescents to adults and older people. The Consumer Healthcare business develops and markets products in Wellness, Oral health, Nutrition and Skin health categories. Its product portfolio includes Adartrel, Bexsero, Daraprim and Quinvaxem. Its brands include Panadol, abreva, polident and physiogel.

Directors: Emma Walmsley (CEO) 49, Iain Mackay (CFO) 55, Roger Connor (CEX) , Brian McNamara (CEX) 50, Luke Miels (CEX) , Regis Simard (CEX) , Phil Thomson (CEX) , Daniel Troy (SVP) , Claire Thomas (SVP) , Nick Hirons (SVP) , Philip Hampton (NEC) 64, Roy Anderson (NID) 70, Marvinder Banga (NID) 63, Vivienne Cox (NID) 60, Lynn Elsenhans (NID) 62,

No. of Employees: 95,490 No. of Shareholders: 109,855


Last Annual December 31st, 2018
Last Interim March 31st, 2019
Incorporated December 6, 1999
Public Since May 22, 1972
Shares in Issue 4,987,960,446
Free Float 4.93bn (98.9%)

Address 980 Great West Road, BRENTFORD, TW8 9GS, United Kingdom
Web https://www.gsk.com/
Phone +44 20 80475000
Contact ()
Auditors PricewaterhouseCoopers LLP

GSK Share Price Performance GSK Share Price Quote
1593p
16.6  1.1%
Traded 4:44pm · Minimum 15 min delayed · NMS: 1.50k

Latest GSK News Announcements (delayed)

Upcoming GSK Events
Wednesday 24th July, 2019
Q2 2019 GlaxoSmithKline PLC Earnings Release
Thursday 26th September, 2019
GlaxoSmithKline PLC Vaccines Investor Event
Wednesday 30th October, 2019
Q3 2019 GlaxoSmithKline PLC Earnings Release

Recent ↓
Friday 21st June, 2019
Valneva SE to Announce Agreement with GlaxoSmithKline PLC to End Strategic Alliance Agreement Call
Wednesday 12th June, 2019
GlaxoSmithKline PLC at Goldman Sachs Global Healthcare Conference
Thursday 6th June, 2019
GlaxoSmithKline PLC at Jefferies Healthcare Conference
Tuesday 4th June, 2019
GlaxoSmithKline PLC at Bernstein Consumer Health & Nutrition Seminar
Thursday 16th May, 2019
Dividend For GSK.L
Thursday 16th May, 2019
Dividend For GSK.N
Thursday 16th May, 2019
Dividend For GSK.BA
Wednesday 8th May, 2019
GlaxoSmithKline PLC Ordinary Shareholders Meeting
Wednesday 8th May, 2019
GlaxoSmithKline PLC Annual Shareholders Meeting
Wednesday 1st May, 2019
Q1 2019 GlaxoSmithKline PLC Earnings Call
Wednesday 1st May, 2019
Q1 2019 GlaxoSmithKline PLC Earnings Release
Tuesday 30th April, 2019
GlaxoSmithKline PLC ViiV Healthcare Investor Event
Tuesday 12th March, 2019
GlaxoSmithKline PLC at Cowen Health Care Conference
Thursday 28th February, 2019
GlaxoSmithKline PLC at Leerink Partners Global Healthcare Conference
Thursday 21st February, 2019
Dividend For GSK.L
Thursday 21st February, 2019
Dividend For GSK.N
Thursday 21st February, 2019
Dividend For GSK.BA
Thursday 14th February, 2019
GlaxoSmithKline PLC at Guggenheim Partners Oncology Day
Wednesday 6th February, 2019
Q4 2018 GlaxoSmithKline PLC Earnings Call
Wednesday 6th February, 2019
Q4 2018 GlaxoSmithKline PLC Earnings Release


Use of our data service is subject to express Terms of Service. Please see our full site disclaimer for more details. In particular, it is very important to do your own research (DYOR) and seek professional advice before making any investment based on your own personal circumstances. Please note that the information, data and analysis contained within this stock report: (a) include the proprietary information of Stockopedia's third party licensors and Stockopedia; (b) should not be copied or redistributed except as specifically authorised; and (c) are not warranted to be complete, accurate or timely. You should independently research and verify any information that you find in this report. Stockopedia will not be liable in respect of any loss, trading or otherwise, that you may suffer arising out of such information or any reliance you may place upon it. Past performance is no guarantee of future results. The value and income derived from investments may go down as well as up. © Stockopedia 2019.


Should you buy GSK

Access GSK Analytics Now!

FREE TRIAL or TAKE THE TOUR
Let’s get you setup so you get the most out of our service
Done, Let's add some stocks
Brilliant - You've created a folio! Now let's add some stocks to it.

  • Apple (AAPL)

  • Shell (RDSA)

  • Twitter (TWTR)

  • Volkswagon AG (VOK)

  • McDonalds (MCD)

  • Vodafone (VOD)

  • Barratt Homes (BDEV)

  • Microsoft (MSFT)

  • Tesco (TSCO)
Save and show me my analysis